Daymara Mercerón-Martínez, Laura Alacán Ricardo, Arturo Bejerano Pina, Norma Orama Rojo, Ariel Expósito Seco, Yamilé Vega Hurtado, Bárbara Estupiñán Días, Isabel Fernández, Laura García Pupo, Marquiza Sablón Carrazana, Chryslaine Rodríguez-Tanty, Roberto Menéndez Soto Del Valle, William Almaguer-Melian
Alzheimer's disease is the most common neurodegenerative disease, and its treatment is lacking. In this work, we tested Amylovis-201, a naphthalene-derived compound, as a possible therapeutic candidate for the treatment of AD. For this purpose, we performed three experiments. In the first and third experiment, animals received a bilateral administration of streptozotocin and, starting 24 h after injection, a daily dose of Amylovis-201 (orally), for 17 days or for the whole time of the experiment respectively (28 days), after which learning and memory, as well as the number of hippocampal dentate gyrus cells, were assessed...
March 1, 2024: Brain Research